AR117715A1 - Interferón hiperglicosilado con inmunogenicidad reducida - Google Patents

Interferón hiperglicosilado con inmunogenicidad reducida

Info

Publication number
AR117715A1
AR117715A1 ARP190103715A ARP190103715A AR117715A1 AR 117715 A1 AR117715 A1 AR 117715A1 AR P190103715 A ARP190103715 A AR P190103715A AR P190103715 A ARP190103715 A AR P190103715A AR 117715 A1 AR117715 A1 AR 117715A1
Authority
AR
Argentina
Prior art keywords
interferon
reduced immunogenicity
hyperglycosylated
nucleic acid
acid molecule
Prior art date
Application number
ARP190103715A
Other languages
English (en)
Spanish (es)
Inventor
William D Martin
Groot Anne Searls De
Marina Etcheverrigaray
Sofa Ins Giorgetti
Eduardo Federico Mufarrege
Original Assignee
Univ Nacional Del Litoral Unl
Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Epivax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nacional Del Litoral Unl, Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet, Epivax Inc filed Critical Univ Nacional Del Litoral Unl
Priority to ARP190103715A priority Critical patent/AR117715A1/es
Priority to PCT/US2020/065246 priority patent/WO2021126929A1/en
Priority to JP2022537837A priority patent/JP7786010B2/ja
Priority to MX2022007546A priority patent/MX2022007546A/es
Priority to US17/783,948 priority patent/US20230127506A1/en
Priority to BR112022011975A priority patent/BR112022011975A2/pt
Priority to EP20901063.6A priority patent/EP4076504A4/en
Publication of AR117715A1 publication Critical patent/AR117715A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP190103715A 2019-12-17 2019-12-17 Interferón hiperglicosilado con inmunogenicidad reducida AR117715A1 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ARP190103715A AR117715A1 (es) 2019-12-17 2019-12-17 Interferón hiperglicosilado con inmunogenicidad reducida
PCT/US2020/065246 WO2021126929A1 (en) 2019-12-17 2020-12-16 Modified interferon-alpha-2 having reduced immunogenicity
JP2022537837A JP7786010B2 (ja) 2019-12-17 2020-12-16 免疫原性が低下した修飾インターフェロン－アルファ－２
MX2022007546A MX2022007546A (es) 2019-12-17 2020-12-16 Interferon-alfa-2 modificado que tiene inmunogenicidad reducida.
US17/783,948 US20230127506A1 (en) 2019-12-17 2020-12-16 Modified interferon-alpha-2 having reduced immunogenicity
BR112022011975A BR112022011975A2 (pt) 2019-12-17 2020-12-16 Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo
EP20901063.6A EP4076504A4 (en) 2019-12-17 2020-12-16 MODIFIED INTERFERON ALPHA-2 WITH REDUCED IMMUNOGENICITY

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP190103715A AR117715A1 (es) 2019-12-17 2019-12-17 Interferón hiperglicosilado con inmunogenicidad reducida

Publications (1)

Publication Number Publication Date
AR117715A1 true AR117715A1 (es) 2021-08-25

Family

ID=76478524

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103715A AR117715A1 (es) 2019-12-17 2019-12-17 Interferón hiperglicosilado con inmunogenicidad reducida

Country Status (7)

Country Link
US (1) US20230127506A1 (https=)
EP (1) EP4076504A4 (https=)
JP (1) JP7786010B2 (https=)
AR (1) AR117715A1 (https=)
BR (1) BR112022011975A2 (https=)
MX (1) MX2022007546A (https=)
WO (1) WO2021126929A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
CN120051483A (zh) 2022-08-18 2025-05-27 再生元制药公司 干扰素前蛋白及其用途
CN121752592A (zh) 2023-05-12 2026-03-27 再生元制药公司 干扰素受体拮抗剂及其用途
CN116814595B (zh) * 2023-08-30 2023-11-28 江苏申基生物科技有限公司 一种腺苷脱氨酶突变体及其固定化

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US20060062761A1 (en) * 2001-03-02 2006-03-23 Carr Francis J Modified interferon alpha with reduced immunogenicity
WO2006020580A2 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
AU2006255122B2 (en) 2005-06-03 2010-10-21 Ambrx, Inc. Improved human interferon molecules and their uses
AU2006263331B2 (en) 2005-06-29 2012-02-16 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Recombinant interferon alpha2 (IFNalpha2) mutants
AR057215A1 (es) 2006-12-01 2007-11-21 Univ Nac Del Litoral Unl Proteina de fusion
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CA2695543A1 (en) 2007-08-06 2009-02-12 Schering Corporation Gamma secretase modulators
US10544199B2 (en) 2014-10-29 2020-01-28 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha 2B variants
AR102120A1 (es) 2015-09-29 2017-02-08 Univ Nac Del Litoral Interferón modificado con inmunogenicidad reducida
WO2019147837A2 (en) 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine fusion proteins

Also Published As

Publication number Publication date
EP4076504A1 (en) 2022-10-26
BR112022011975A2 (pt) 2022-08-30
JP2023514659A (ja) 2023-04-07
MX2022007546A (es) 2022-11-30
US20230127506A1 (en) 2023-04-27
WO2021126929A1 (en) 2021-06-24
EP4076504A4 (en) 2024-04-10
JP7786010B2 (ja) 2025-12-16

Similar Documents

Publication Publication Date Title
AR117715A1 (es) Interferón hiperglicosilado con inmunogenicidad reducida
PE20211469A1 (es) Proteinas f de prefusion del vrs estabilizadas
MX2021010559A (es) Polipéptidos efectores de crispr-cas y métodos de uso de estos.
EA201892671A1 (ru) Пегилированный свиной интерферон и способы его применения
HRP20231496T1 (hr) Cistein proteaza
BR112018073909A2 (pt) proteínas klotho recombinantes terapêuticas e composições e métodos envolvendo as mesmas
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
ATE479704T1 (de) Antimikrobielle peptide mit einem arginin- und /oder lysin-haltigen motiv
AR087091A1 (es) Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso
DK1668031T3 (da) Homogene præparater af IL-29
AR087227A1 (es) CONJUGADO DE INTERFERON a CON POLIETILENGLICOL
IL288541B (en) Vaccine against rsv
MX2022014411A (es) Polipéptidos il-12 activables y métodos de uso de estos.
MY206268A (en) Modified s1 subunit of the coronavirus spike protein
JP2017513503A5 (https=)
CL2019003409A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
BR112021023957A2 (pt) Peptídeos
HRP20191965T1 (hr) Stabilizirani polipeptidi faktora rasta slični inzulinu
BR112022010321A2 (pt) Composições e métodos para tratamento de neuropatia óptica hereditária de leber com proteínas nadh desidrogenase
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
PE20251395A1 (es) Proteinas de fusion de hmpv de prefusion estabilizadas
CA2692358A1 (en) Recombinant human interferon-like proteins
JP2020516322A5 (https=)
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico